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Abstract
Background Bisphosphonates have become the treatment
of choice for a variety of bone diseases in which excessive
osteoclastic activity is an important pathologic feature.
However, inhibition of osteoclastic activity could lead to
inhibition of remodeling during bone healing or repair. The
objective of this study is to investigate the effect of
zoledronate (the most potent bisphosphonate) in the bio-
logical process of bone healing.
Methods Thirty immature male rabbits were divided into
two groups (control and experimental) of 15 animals each.
Both groups were submitted to ﬁbular osteotomy. Only in
the experimental group a single dose of zoledronate was
administered. After 1, 2, and 4 weeks, animals of both
groups were euthanized and the osteotomy site was histo-
morphometrically evaluated. The associated parameters
analyzed were tissue volume (TV), fractional trabecular
bone volume (BV/TV), fractional woven bone volume
(WoV/TV), fractional periosteal ﬁbrous volume (FbV/TV),
and medullary ﬁbrous volume (MaV/TV).
Results The ﬁrst week of healing was characterized by
small callus area (experimental group) and less periosteal
ﬁbrosis. The second week was characterized by a large
quantity of woven bone and marked decrease in periosteal
ﬁbrosis in the two groups. In the control group there was
also a signiﬁcant increase in trabecular bone. The fourth
week was characterized by increased amount of woven
bone and trabecular bone in the experimental group; there
was increased medullary ﬁbrosis in the two groups, while
there continued to be signiﬁcantly less periosteal ﬁbrosis in
the experimental group.
Conclusions Zoledronate does not prevent bone healing.
However, the effect of zoledronate was characterized by
accentuated stimulation of primary bone production and
probably inhibition of remodeling, leading to retention of
trabecular bone.
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Introduction
Bisphosphonates (BS) can be classiﬁed into two major
groups. The ﬁrst group comprises the non-nitrogen-con-
taining BS and the second group contains the more potent,
nitrogen-containing BS such as alendronate, pamidronate,
risedronate, and zoledronate (ZA). Members of the second
group interfere with the mevalonate biosynthetic pathway
and affect cellular activity and cell survival by interfering
with protein prenylation [1]. Prenylation is required for
important signaling proteins that regulate a variety of cell
processes important to osteoclast function, including cell
morphology, cytoskeletal arrangement, membrane rufﬂing,
trafﬁcking of vesicles, and apoptosis [2]. Bone resorption is
mediated by osteoclasts and its activity can be reduced by
systemic BS treatment.
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inhibitorsofboneresorption,especiallyfordiseasesforwhich
no effective treatment existed previously. Thus, BS have
become the treatment of choice for a variety of bone diseases
in which excessive osteoclastic activity is an important
pathologic feature, including Paget’s disease of bone, meta-
static and osteolytic bone disease, hypercalcemia of malig-
nancy, osteogenesis imperfecta, as well as osteoporosis [3].
In spite of BS treatment, pathologic fractures and the need
for surgical orthopedic treatments that require bone remod-
eling are common in such diseases. Inhibition of osteoclastic
activity could lead to inhibition of remodeling during bone
healing or repair or bone graft incorporation. As inhibitors of
remodeling, the effects of BS during these processes remain
unknown and could constitute a negative inﬂuence [1–3].
The effects of BS on fracture healing have been inves-
tigated after administration of clodronate, alendronate,
etidronate, and incadronate [4–6]. Most of the previous
studies did not report signiﬁcant changes during fracture
repair, while others showed slight improvement in the
amount of bone formed. Kiely et al. [7] showed increase in
new bone formation when zoledronate was used in a dis-
traction osteogenesis model and suggested that BS could
have a positive effect for that drug. Zoledronate also
improves the amount of bone in the metaphysis during bone
healing, suggesting a positive effect on remodeling [8].
Zoledronate is the most potent BS in clinical use and its
effects on remodeling could demonstrate the role of this
group of drugs during repair or bone healing process more
than any other BS. The objective of this study is to check
the effect of zoledronate in the biological process of bone
healing, in a controlled experimental model in rabbits
submitted to ﬁbular osteotomy in accordance with the
method described by Matos et al. [9, 10].
Materials and methods
This study conformed to the guiding principles of the
Declaration of Helsinki involving experimental animals
and was approved by the Research Ethics Committees at
the University of Sa ˜o Paulo and at the Bahia School of
Medicine and Public Health.
Animals: experimental groups
Thirty immature male albino New Zealand rabbits were
divided into two groups of 15 animals each, assigned to the
control and experimental group, respectively. The animals
were 6–8 weeks old when the experiment began in both
groups. Initial weight was 918 g in the control group and
875 g in the experiment group (no signiﬁcant difference
between groups by t-test).
The animals were acclimatized in the animal care
facility for several days and were housed in individual
cages during the entire study period with water and pellet
chow diet ad libitum.
Experimental design
Food was suspended 8–10 h prior to administering anes-
thesia. To decrease the vagal tonus, each animal received
0.2 mg/kg atropine sulfate by intramuscular injection.
Animals were anesthetized by intraperitoneal injection of
ketamine (25.0–30.0 mg/kg body weight) and intramus-
cular injection of diazepam (5.0–10.0 mg/kg body weight).
This experimental osteotomy model in rabbits was
reported by Matos et al. [9]. Under aseptic technique
conditions, the ﬁbula of each animal was accessed by
approximately 5-mm lateral incision on the right pelvic
limb. After division of the skin and subcutaneous tissue,
the fascia of ﬁbular muscles and periosteum were opened
and dissected from the cranial portion of the ﬁbula. Shaft
osteotomy was performed on the cranial portion of the
exposed ﬁbula, using an electric saw with a standardized
blade (10.0 mm wide, 0.5 mm thick). The incision was
closed in layers, using absorbable 5-0 polyvicryl sutures for
the fascia and 5-0 mononylon sutures for the skin.
In the experimental group (group 2), a single dose of
0.04 mg/kg zoledronate was administered via intraperito-
neal injection immediately before the surgical procedure.
In the control group (group 1), the same volume of double-
distilled water was administered under similar conditions.
Both groups were submitted to the same procedure. After
that, groups 1 and 2 were divided into subgroups A, B, and
C, containing ﬁve animals each, designated 1A, 1B, and 1C
for control, and 2A, 2B, and 2C for experiment.
After 1 (subgroups A), 2 (for subgroups B), and 4 weeks
(subgroups C), animals of both groups were anesthetized
and euthanized by intracardiac injection of 2 ml potassium
chloride. The ﬁbula of each animal was removed, dissected
from the surrounding soft tissue, and ﬁxed in 10% formalin
for microscopic evaluation. Formalin-ﬁxed bones were
decalciﬁed with 7.5% nitric acid, embedded in parafﬁn, and
longitudinally sectioned. Histological sections (7 lm thick)
were stained with hematoxylin and eosin prior to optical
microscope examination.
Histomorphometric evaluation of the callus
Three histological sections were analyzed for each animal.
After the cuts had been chosen, preliminary analysis was
performed at 1009 magniﬁcation in order to deﬁne the area
of the callus, deﬁned by the regions associated with sig-
niﬁcant periosteal thickening, i.e., the area where the cor-
tical bone thickness had more than doubled.
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were performed using a test eyepiece reticule with 10
parallel lines and 100 points in a grid with a total area of
10,500 lm
2 (Zeiss 23-9901) at magniﬁcation of 2009. The
associated parameters analyzed were tissue volume (TV),
fractional trabecular bone volume (BV/TV), fractional
woven bone volume (WoV/TV), fractional periosteal
ﬁbrous volume (FbV/TV), and medullary ﬁbrous volume
(MaV/TV), taken according to previous reports by Praﬁtt
et al. [11] and Matos et al. [10].
Statistical analysis
Difference between mean continuous values was tested
using Student’s t-test (0.05) for parametric data. When
verifying hypotheses for nonparametric data comparing
more than two distributions, the Kruskal-Wallis test was
used, followed by Dunn’s post hoc test (when the proba-
bility of the former was less than 0.05). In comparison of
two independent nonparametric distributions, the Mann–
Whitney test was used at a level of signiﬁcance of 0.05.
Results
Overall assessment
One animal in the experimental group had slight suture
dehiscence but was not withdrawn from the research as it
was a superﬁcial lesion that needed no treatment other than
a dressing. At the end of the study, all the animals in the
two groups were assessed as being in a satisfactorily
healthy condition.
Microscopic assessment
The appearance of the bone callus seen under 409 mag-
niﬁcation conﬁrmed that there were no cases of pseudar-
throsis. The microscopic appearance was similar in an
overall and qualitative manner. Staining with hematoxylin
and eosin allowed good distinction between the bone tissue
in primary structure (woven bone), mature bone in tra-
becular structure, periosteal ﬁbrosis, and medullary
ﬁbrosis.
Histomorphometric analysis was performed, quantifying
the parameters mentioned in ‘‘Materials and methods’’.
Testing of differences in relation to time (in the rows of the
tables) was checked by the Kruskal-Wallis test and marked
with ‘‘#’’ (hash) for P\0.05 in relation to subgroup 1A;
testing of the differences among the control and experi-
mental groups (in the columns of tables) was checked by
Mann–Whitney test and marked with ‘‘*’’ (asterisk) for
P\0.05.
The ﬁrst week of consolidation was characterized by
large callus area (signiﬁcantly smaller in the experimental
group), a large amount of periosteal ﬁbrosis (signiﬁcantly
less in the experimental group), little medullary ﬁbrosis,
and little trabecular bone. The second week was charac-
terized by a large quantity of woven bone and marked
decrease in periosteal ﬁbrosis in the two groups. In the
control group there was also signiﬁcant increase in tra-
becular bone. The fourth week was characterized by
decrease in callus area in the two groups and reduced
amount of woven bone in the control group. The amount of
trabecular bone increased signiﬁcantly in the experimental
group. There was increased medullary ﬁbrosis in the two
groups, while there continued to be signiﬁcantly less
periosteal ﬁbrosis in the experimental group. The results of
this histomorphometric analysis are presented in Figs. 1
and 2 and Tables 1–5.
Fig. 1 Histologic section of the callus in the control group during the
fourth week of healing (HE, 1009)
Fig. 2 Histologic section of the callus in the experimental group
during the fourth week, showing a large amount of woven bone
compared with the control group (HE, 1009)
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The process of bone and fracture repair can be considered
as consisting of anabolic (bone-forming) and catabolic
(bone-resorbing) responses. The ﬁrst step of this process is
characterized by endochondral ossiﬁcation that produces a
nonmineralized cartilage scaffold. Osteoblastic cells then
lay down new bone on chondral remnant tessues to produce
Table 1 Tissue volume (TV) mm
3
Group First week
Mean (standard deviation)
Second week
Mean (standard deviation)
Fourth week
Mean (standard deviation)
Control 314 (59)
*# 183 (45) 132.4 (31)
#
Experimental 187.2 (10.6)
*# 180.8 (8.5) 135.2 (24.1)
#
# P\0.05 for Kruskal-Wallis and Dunn’s tests intragroup
* P\0.05 for Mann–Whitney test intergroup
Table 2 Fractional woven bone volume (WoV/TV)
Group First week
Mean (standard deviation)
Second week
Mean (standard deviation)
Fourth week
Mean (standard deviation)
Control 18.9 (4.2)
# 17.4 (6.3) 2.8 (2.7)
*#
Experimental 23.6 (4.6) 23.2 (10) 16.1 (12)
*
# P\0.05 for Kruskal-Wallis and Dunn’s tests intragroup
* P\0.05 for Mann–Whitney test intergroup
Table 3 Fractional trabecular bone volume (BV/TV)
Group First week
Mean (standard deviation)
Second week
Mean (standard deviation)
Fourth week
Mean (standard deviation)
Control 7.6 (2.8)
# 28.2 (3.9)
# 25.9 (5.3)
Experimental 10 (2.3)
# 25.4 (7.2) 31 (6.8)
#
# P\0,05 for Kruskal-Wallis and Dunn’s tests intragroup
* P\0,05 for Mann–Whitney test intergroup
Table 4 Fractional medullary ﬁbrous volume (MaV/TV)
Group First week
Mean (standard deviation)
Second week
Mean (standard deviation)
Fourth week
Mean (standard deviation)
Control 3.9 (2.5)
# 15.8 (1.9) 19.2 (5.2)
#
Experimental 6.3 (2.4)
# 21.9 (10.5) 29.8 (16.4)
#
# P\0.05 for Kruskal-Wallis and Dunn’s tests intragroup
* P\0.05 for Mann–Whitney test intergroup
Table 5 Fractional periosteal ﬁbrous volume (FbV/TV)
Group First week
Mean (standard deviation)
Second week
Mean (standard deviation)
Fourth week
Mean (standard deviation)
Control 55.2 (8)
*# 17.3 (4.9)
*# 17.3 (4.9)
*#
Experimental 42.9 (8.7)
*# 8 (2.7)
*# 8.4 (3.6)
*
# P\0.05 for Kruskal-Wallis and Dunn’s tests intragroup
* P\0.05 for Mann–Whitney test intergroup
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123primary bone. At this stage, remodeling starts to occur,
with osteoclastic resorption followed by formation of new
lamellar bone [12].
We ﬁnd that zoledronate (ZA) does not prevent bone
healing. The callus under the effect of ZA showed larger
callus area and a signiﬁcant increase of woven bone and
trabecular bone. The effect of ZA was characterized by
accentuated stimulation of primary bone production and
probably inhibition of remodeling, leading to retention of
trabecular bone.
Our ﬁndings suggest that inhibition of bone resorption
did not affect the ﬁrst stages of the repair process. It is
important to note also that bone remodeling is not a
requirement for initial fracture repair. Although osteoclasts
may contribute to endochondral ossiﬁcation, these pro-
cesses are not inherently dependent on osteoclasts [13].
We ﬁnd not only decreased resorption as expected, but
also an increased amount of new bone in the callus area in
the fourth week. During remodeling phase our ﬁndings
support the idea that BS can decrease bone resorption while
osteoblasts continue their anabolic activity. This leads to an
increased amount of woven bone by the delay in resorption
or retention of primary formed bone during that phase,
suggesting that BS would be not merely an anticatabolic
but also an anabolic drug.
The effects of BS on fracture healing have been inves-
tigated after administration of clodronate, alendronate,
etidronate, and incadronate [4–6]. Most of the previous
studies did not result in signiﬁcant changes during fracture
repair, while others have shown slight improvement in the
amount of bone formed. Peter et al. [6] reported that
alendronate does not inhibit bone formation; however, the
callus presented a volume two to three times larger. Li et al.
[5] found that incadronate causes a decrease in resorption,
but there was signiﬁcant increase of bone volume only in
the group treated with high doses 4 weeks later. Pamidro-
nate-treated bones also showed greater callus area and
reduced remodeling, but healing was not prevented [14].
Zoledronate is more potent than any other BS and its
biological actions are only similar to those of pamidronate.
It is not possible to extrapolate results of one compound to
others, but all of them tend to produce greater callus
without healing impairment. Amanat et al. [15] investi-
gated use of zoledronate to improve bone repair and found
that the drug increases callus bone mineral content (BMC),
volume, and mechanical strength. Another study conducted
by McDonald et al. [16] revealed that zoledronate causes
signiﬁcant retention of primary trabecular bone, leading to
a larger, stronger callus with reduced inhibition of primary
callus remodeling. These previous studies conﬁrm and
support our ﬁndings, but none of the previous reports
studied bone repair based on histomorphometric
parameters.
The anabolic effect of BS has been hypothesized in
several studies [17, 18]. Some experimental studies suggest
that BS may protect osteocytes and osteoblasts from
apoptosis induced by glucocorticoids [19]. Inhibition of
osteocyte apoptosis is mediated through the opening of
connection 43 hemichannels and activation of extracellular
signal-regulated kinases [18].
Several other recent studies raised the intriguing possi-
bility that BS may enhance fracture repair and related pro-
cesses [17]. In a distraction osteogenesis model, Kiely et al.
[7] showed that decreased catabolism allows increased net
bone accumulation in the regenerate during pamidronate or
zoledronate treatment. Wedemeyer et al. [20], in a murine
calvarial osteolysis model, showed increased osteoblastic
activity and osteoid formation; those authors hypothesized
that osteoblasts exposed to a single dose of zoledronate are
able to increase their bone-forming potential.
Litle et al. [17] showed that zoledronate can increase
callus volume, bone mineral content, bone, and trabecular
volume in a femoral critical defect model. Finally,
McDonald et al. [16] reported that zoledronate increases
callus volume and leads to retention of primary trabecular
bone during fracture healing.
The fact that we found an increased amount of newly
formed bone does not necessarily mean that more bone has
formed or that zoledronate is by any means anabolic. New
formed bone might simply just prevail for a longer period if
bone resorption is reduced. Regardless of the reason, bone
formation during healing was not decreased in our study,
and more bone was found in the callus area. This conﬁrms
that zoledronate could have an anabolic result by either
stimulating or mimicking increased new bone formation.
To our knowledge this is the ﬁrst study to show an
impressive anabolic effect of BS during fracture healing by
means of histomorphometric evaluation. This is an
important ﬁnding and may give support to studies that aim
to prove clinical beneﬁts of these drugs in pathologic
conditions in which bone repair may be involved such as
pseudarthrosis, pathologic fracture, incorporation of bone
grafts, and of course, healing of osteotomy in patients
suffering from metabolic bone diseases.
Conﬂict of interest None.
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